3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Breast Neoplasms
11
Prostatic Neoplasms
10
Glioblastoma
10
Oropharyngeal Neoplasms
7
Rectal Neoplasms
6
Neoplasms
6
Lung Neoplasms
6
Astrocytoma
6
Squamous Cell Carcinoma of Head and Neck
5
Urinary Bladder Neoplasms
4
Burkitt Lymphoma
4
Adenocarcinoma of Lung
4
Pancreatic Neoplasms
3
Nasopharyngeal Carcinoma
3
Mouth Neoplasms
3
Lymphoma, Follicular
3
Hodgkin Disease
3
Gliosarcoma
3
Glioma
3
Esophageal Neoplasms
3
Carcinoma, Squamous Cell
3
Carcinoma
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Rhabdomyosarcoma
2
Neoplasm, Residual
2
Mesothelioma, Malignant
2
Meningeal Carcinomatosis
2
Lymphoma, Large B-Cell, Diffuse
2
Interventions
pembrolizumab
32
Paclitaxel
14
Carboplatin
12
Cisplatin
10
lenvatinib
7
Pemetrexed
6
belzutifan
4
Oxaliplatin
4
Gemcitabine
4
Fluorouracil
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
patritumab deruxtecan
3
olaparib
3
Leucovorin
3
Docetaxel
3
Acetaminophen
3
130-nm albumin-bound paclitaxel
3
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Dexamethasone
2
Cetuximab
2
Bevacizumab
2
Axitinib
2
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Radiotherapy
×
30 days
×
Clear all
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled